Mirabegron Sandoz,Betmiga 50 mg

3 trials

Sponsors

Novartis (Thailand) Ltd.

Conditions

Healthy Volunteers Bioequivalence Mirabegron Pharmacokinetics Healthy VolunteersOveractive bladder syndrome Overactive bladder syndrome OABOveractive bladder syndrome Overactive bladder syndrome OAB

Phase 1

A Bioequivalence Study of Two Formulations of 50-mg Mirabegron Prolonged Release Tablets in Healthy Thai Volunteers under Fasting Conditions

Active, not recruitingTCTR20220223005

Novartis (Thailand) Ltd.Overactive bladder syndrome Overactive bladder syndrome OAB

Start: 2022-06-15Target: 54Updated: 2026-08-03

A Bioequivalence Study of Two Formulations of 50-mg Mirabegron Prolonged Release Tablets in Healthy Thai Volunteers under Fed Conditions

Active, not recruitingTCTR20220223006

Novartis (Thailand) Ltd.Overactive bladder syndrome Overactive bladder syndrome OAB

Start: 2022-06-27Target: 44Updated: 2026-08-03

A Bioequivalence Study of Two Formulations of Mirabegron 50-mg Prolonged-release Tablets in Healthy Thai Subjects under Fasting Conditions

TCTR20230713003

Novartis (Thailand) Ltd.Healthy Volunteers Bioequivalence Mirabegron Pharmacokinetics Healthy Volunteers

Start: 2023-10-15Target: 72Updated: 2026-08-03